awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5
Q26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
P2860
Q26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26740070-B730AF4A-5BC7-4F2C-A8D7-0AF5E8B1DED5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
00eadf49d4f3bbe8d8e14852395572c11c6252f8
P2860
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.